Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Abstract: A problem of the present invention is to provide an agent which allows effective protection of cardiac damage in a case where a variety of symptoms such as arrhythmia, cardiac desmoplasia and heart-failure are likely to accompany with hypertension, hypercardia, myocardial infarction, arteriosclerosis, diabetic and non-diabetic renal diseases, and re-stenosis posterior to PTCA. The agent contains an effective amount of at least one protease inhibitor to administer intravenously or orally. The protease inhibitor is preferably a serine protease inhibitor. The serine protease inhibitor is preferably a chymotrypsin-like serine protease inhibitor. Concretely, it is a chymase inhibitor such as a peptide derivative of aryl diester of alpha-aminoalkylphosphonic acid which is Suc-Val-Pro-PheP(OPh)2, and preferably the enantiormer Suc-Val-Pro-L-PheP(OPh)2.

Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Abstract: A problem of the present invention is to provide a medicament which allows effective prevention, inhibition, or treatment of adhesion formation, comprising using before or after a variety of surgical treatments including orthopedic or plastic surgery, for example, in cardiac, thoracic, gynecological, ophthalmic, abdominal sites or in the case where injury or inflammation can cause adhesion in visceral organs. The medicament contains an effective amount of at least one protease inhibitor to administer intravenously, orally, or percutaneously. The protease inhibitor is preferably a serine protease inhibitor, and the serine protease inhibitor is a chymotrypsin-like serine protease inhibitor. Specifically, it is a chymase inhibitor, the peptide derivative of an aryl diester of alpha-aminoalkylphosphonic acid, Suc-Val-Pro-PheP(OPh)2, and preferably the enantiomer, Suc-Val-Pro-L-PheP(OPh)2.

Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Abstract: The present invention relates to a therapeutic or prophylactic agent for an angiostenosis comprising as an active ingredient a compound having a pyrimidone skeleton and having chymase inhibiting activity, for example, a compound having a structure represented by the following Formula (II) 1

Abstract: The present invention generally provides methods for the prevention or reduction of adhesion formation/reformation using protease inhibitors. More specifically, this invention provides methods for preventing or inhibiting postoperative adhesion formation/reformation in mammals following surgical or accidental injury or inflammation to the organs of the peritoneal or pleural cavity or other body spaces, using serine protease inhibitors, such as, for example, using chymase inhibitors (e.g., &agr;-aminoalkylphosphonate derivatives) and the like.

Abstract: The present invention relates to an N-substituted benzothiophenesulfonamide derivative or a pharmaceutically acceptable salt thereof and applications thereof. Furthermore, it provides an agent for preventing or treating cardiac or circulatory disease and so on caused by abnormal increase of production of angiotensin II or endothelin I based on chymase activity, or by activation of mast cell, and an agent for preventing adhesion after surgery, wherein the agent has a selective inhibitory action on chymase.

Abstract: An agent for the prophylaxis or treatment of muscle tissue degeneration, containing, as an active ingredient, a quinoline compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt. The prophylactic or therapeutic agent of muscle tissue degeneration of the present invention contains a quinoline compound of the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and shows remarkable inhibitory or improving action on degeneration of the muscle tissues such as necrosis, fibrosis, calcification and the like. The agent is specifically useful for the prophylaxis and treatment of cardiomyopathy, muscular dystrophy, pulmonary fibrosis and the like.

Abstract: Heterocyclic amide compounds of the formula (I) ##STR1## wherein each symbol is as defined in the specification, pharmacologically acceptable salts thereof, pharmaceutical compositions thereof and pharmaceutical use thereof. The heterocyclic amide compounds and pharmacologically acceptable salts thereof of the present invention have superior inhibitory activity against chymase groups in mammals inclusive of human, and can be administered orally or parenterally. Therefore, they are useful as chymase inhibitors and can be effective for the prophylaxis and treatment of various diseases caused by chymase, such as those caused by angiotensin II.